Eli Lilly reduces Zepbound price via single-dose vials through LillyDirect telehealth platform.

Eli Lilly is reducing the price of its popular weight loss drug, Zepbound, due to high demand and supply limitations. The company is offering Zepbound in single-dose vials through its telehealth platform LillyDirect, which connects patients with providers capable of prescribing obesity drugs. This lower-cost option may expand access for patients whose insurance plans do not cover powerful weight-loss medications, some of which have been restricted or had coverage suspended by insurers to manage rising costs. The move aims to combat competition from telehealth companies offering weight-loss drugs and could pose a challenge to them.

August 27, 2024
589 Articles